Application of recombinant histone protein H1.3 for inhibition of adenoviral infection



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There is an ongoing search for new drugs for the treatment of adenovirus infections. In our work the antiviral properties of the recombinant histone H1.3 in in vitro cell culture was investigated and for the first time we demonstrated that recombinant histone H1.3 significantly reduces the efficiency of adenoviral transduction. Also, recombinant histone H1.3 exerts an inhibitory effect on plaque formation on HEK-293A cells monolayer, infected with adenovirus serotype 5, which confirms antiviral properties of histone H1.3 towards adenoviruses.

Full Text

Restricted Access

About the authors

V. V Solovyeva

Kazan (Volga region) Federal University

A. A Rizvanov

Kazan (Volga region) Federal University

References

  1. Kinchington P.R., Romanowski E.G., Gordon Y.J. Prospects for adenovirus antivirals. J. Antimicrob. Chemother. 2005; 55(4): 424-9.
  2. Waye M.M.Y., Sing C.W. Anti-Viral Drugs for Human Adenoviruses. Pharmaceuticals. 2010; 3: 3343-3354.
  3. Hillenkamp J., Reinhard T., Ross R.S. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002; 109(5): 845-50.
  4. Engelmann G., Heim A., Greil J. Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr. Transplant. 2009; 13(4): 421-8.
  5. Bhadri V.A., Lee-Horn L., Shaw P.J. Safety and tolerability of cidofovir in high-risk pediatric patients. Transpl. Infect. Dis. 2009; 11(4): 373-9.
  6. Gavin P.J., Katz B.Z. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002; 110(1 Pt 1): e9.
  7. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23(8): 583-8.
  8. Sumida S.M., Truitt D.M., Lemckert A^., Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005; 174(11): 7179-85.
  9. Cao Y., Lam L. Bispecific antibody conjugates in therapeutics. Adv. Drug. Deliv. Rev. 2003; 55(2): 171-97.
  10. Соловьева В.В., Кудряшова Н.В., Ризванов А.А. Перенос рекомбинантных нуклеиновых кислот в клетки (трансфекция) с помощью гистонов и других ядерных белков. Клеточная Трансплантология и Тканевая Инженерия. 2011; 6(3): 29-40.
  11. Reichhart R., Zeppezauer М., Jornvall H. Preparations of homeostatic thymus hormone consist predominantly of histones 2A and 2B and suggest additional histone functions. PNAS USA. 1985; 82(15): 4871-5.
  12. Reichhart R., Jornvall H., Carlquist M. The primary structure of two polypeptide chains from preparations of homeostatic thymus hormone (HTH alpha and HTH beta) entire-chain identities to two histones. FEBS Lett. 1985; 188(1): 63-7.
  13. Zeppezauer M., Reichhart R., invertors; Symbiotec Gmbh, assignee. Pure Histone H1 for use in therapeutic procedures. EP0392315 B1. 1994.
  14. Braun J., Targan S.R., Eggena M., invertors; Regents of the Univ. of California, Cedars-Sinai Medical Center, assignees. Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1. US6074835 A. 2000.
  15. Class R., Hand C.M., invertors; Class R.J.W., Hand C.M., assignees. Antimicrobial histone H1 compositions, kits, and methods of use thereof. US20010046976 A1. 2001.
  16. Zeppezauer M., Class R., invertors; Zeppezauer M., Class R., assignees. Use of histones for therapeutic purposes. US20090305966 A1. 2009.
  17. Parks D.R., Bryan V.M., Oi V.T. Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter. PNAS USA. 1979; 76(4): 1962-6.
  18. Giglione C., Vallon O., Meinnel T. Control of protein life-span by N-terminal methionine excision. EMBO J. 2003; 22(1): 13-23.
  19. Gross P., Joernvall H., Thiry M., invertors; Symbiotec Gmbh, assignee. Bis-Met Histones. WO 2008/122434 A1. 2008.
  20. Zhao H., Bose S., Tuominen E.K. Interactions of histone H1 with phospholipids and comparison of its binding to giant liposomes and human leukemic T cells. Biochemistry 2004; 43(31): 10192-202.
  21. Мингалеева Р.Н., Соловьева В.В., Блатт Н.Л. Применение культур клеток и тканей для скрининга противоопухолевых препаратов in vitro. Клеточная трансплантология и тканевая инжененрия 2013; 8(2): 20-8.
  22. Соловьева В.В., Исаев А.А., Генкин Д.Д. Влияние рекомбинантного гистона Н1.3 на эффективность лентивирусной трансдук-ции клеток человека in vitro. Клеточная трансплантология и тканевая инжененрия 2012; 7(3): 151-4.
  23. Liegler T.J., Hyun W., Yen T.S. Detection and quantification of live, apoptotic, and necrotic human peripheral lymphocytes by single-laser flow cytometry. Clin. Diagn. Lab. Immunol. 1995; 2(3): 369-76.
  24. Мартынова Е.В., Данилова Ю.В., Анохин В.А. Биобезопас-ная модель аденовирусной инфекции: влияние бактериальных про-теаз на инфицирование клеток человека in vitro. Клеточная трансплантология и тканевая инженерия 2012; 7(3): 105-7.
  25. Головин Е.В., Мустафин И.Г., Мартынова Е.В. Безопасная модель ВИЧ-инфекции для оценки антиретровирусной активности лекарственных препаратов. Современные технологии в медицине 2012; 1: 55-60.
  26. Altunbek M., Yalvag M.E., Keseroglu K. Gold- and Silver-based Nano-Particles Influence Pseudo-Typed Lenti-viral Infection. Current Nanoscience 2013; 9(6): 693-7.
  27. Graham F.L., Smiley J., Russell W.C. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977; 36(1): 59-74.
  28. Harrison T., Graham F., Williams J. Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 1977; 77(1): 319-29.
  29. Manning J.S., Hackett A.J., Darby N.B. Jr. Effect of polycations on sensitivity of BALD-3T3 cells to murine leukemia and sarcoma virus infectivity. Appl. Microbiol. 1971; 22(6): 1162-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies